Last reviewed · How we verify

NCT03105661

Use of Impedance Cardiography to Decrease the Risk of Pre-eclampsia in Obese Patients

Status unknown EARLY_PHASE1 Last updated 22 February 2019
What this trial tests

EARLY_PHASE1 trial testing Labetalol Hydrochloride 200 mg in Obesity, Morbid in 400 participants. Status unknown.

Timeline
4 April 2017
Primary endpoint
31 December 2019
4 March 2020

Quick facts

Lead sponsorUniversity of Tennessee Graduate School of Medicine
PhaseEARLY_PHASE1
StatusStatus unknown
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingnone
Primary purposeprevention
Enrollment400
Start date4 April 2017
Primary completion31 December 2019
Estimated completion4 March 2020
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

University of Tennessee Graduate School of Medicine

Who can join

Adults 18 to 51, female only, with Obesity, Morbid or Preeclampsia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To determine if the use of impedance cardiography can identify appropriate medications for use in treating morbidly obese patients to decrease the risk of preeclampsia.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Obesity, Morbid

Currently open trials in the same condition.

Other University of Tennessee Graduate School of Medicine trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03105661.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing